Lipiodolizzazione associata o meno a Gelfoam in pazienti con tumore epatico primitivo. Livelli plasmatici di Mitoxantrone e risultati clinici.

Translated title of the contribution: Lipiodol with and without Gelfoam in primary liver tumors. Plasma levels of Mitoxantrone and clinical results

D. Civalleri, M. Esposito, G. De Caro, G. Borgonovo, F. De Cian, G. Mondini, O. Vannozzi, M. M. Bocchio, S. Carrabetta

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Transcatheter chemoembolization with various drugs is employed for palliative treatment of hepatocellular carcinoma. Thirty-seven patients (33 with Child A or B cirrhosis) were treated with 14 mg/m2 of Mitoxantrone and up to 20 ml of Lipiodol, followed by Gelfoam embolization as indicated. Sixty-nine cycles were given, with mean (+/-SD) Lipiodol and emulsified Mitoxantrone doses of 11.3 +/- 3.8 ml and 11.8 +/- 5.2 mg, respectively. Thirteen, 16, and 8 patients received one, two, and three cycles, respectively, with time intervals of 123 +/- 60 days. Thirty patients had Gelfoam embolization at the first cycle, 9 at the second and 4 at the third. At the first cycle, 10 patients underwent serial measurements of serum Mitoxantrone up to two hours after a full dose of emulsified drug. Drug levels resulted much lower than those reported after plain arterial infusion, with AUC levels (+/-SE) of 5924 +/- 1015 and 4381 +/- 429 ng/ml x 120 min in 6 and 4 cases treated with and without Gelfoam, respectively. No treatment related deaths occurred. Complications were mild and transient, including nausea vomiting in most cases, fever > 38 degrees C 67%, pain 74%, ascites 8% jaundice 3%, bleeding 3%, pancreatitis 3%, myelosuppression 44%, diarrhea 5%. Treatment response rate was 49% (including 16% minor response) with 16% early progressions. With a median follow-up of 12 months, the 12-month response duration and survival rates were 56% and 79% respectively. Transcatheter chemoembolization with Mitoxantrone deserves further evaluation in randomized studies.

Original languageItalian
Pages (from-to)362-367
Number of pages6
JournalGiornale di Chirurgia
Volume18
Issue number6-7
Publication statusPublished - Jun 1997

Fingerprint

Absorbable Gelatin Sponge
Ethiodized Oil
Mitoxantrone
Liver
Neoplasms
Pharmaceutical Preparations
Jaundice
Palliative Care
Ascites
Pancreatitis
Nausea
Area Under Curve
Vomiting
Hepatocellular Carcinoma
Diarrhea
Fibrosis
Fever
Survival Rate
Hemorrhage
Pain

ASJC Scopus subject areas

  • Surgery

Cite this

Civalleri, D., Esposito, M., De Caro, G., Borgonovo, G., De Cian, F., Mondini, G., ... Carrabetta, S. (1997). Lipiodolizzazione associata o meno a Gelfoam in pazienti con tumore epatico primitivo. Livelli plasmatici di Mitoxantrone e risultati clinici. Giornale di Chirurgia, 18(6-7), 362-367.

Lipiodolizzazione associata o meno a Gelfoam in pazienti con tumore epatico primitivo. Livelli plasmatici di Mitoxantrone e risultati clinici. / Civalleri, D.; Esposito, M.; De Caro, G.; Borgonovo, G.; De Cian, F.; Mondini, G.; Vannozzi, O.; Bocchio, M. M.; Carrabetta, S.

In: Giornale di Chirurgia, Vol. 18, No. 6-7, 06.1997, p. 362-367.

Research output: Contribution to journalArticle

Civalleri, D, Esposito, M, De Caro, G, Borgonovo, G, De Cian, F, Mondini, G, Vannozzi, O, Bocchio, MM & Carrabetta, S 1997, 'Lipiodolizzazione associata o meno a Gelfoam in pazienti con tumore epatico primitivo. Livelli plasmatici di Mitoxantrone e risultati clinici.', Giornale di Chirurgia, vol. 18, no. 6-7, pp. 362-367.
Civalleri, D. ; Esposito, M. ; De Caro, G. ; Borgonovo, G. ; De Cian, F. ; Mondini, G. ; Vannozzi, O. ; Bocchio, M. M. ; Carrabetta, S. / Lipiodolizzazione associata o meno a Gelfoam in pazienti con tumore epatico primitivo. Livelli plasmatici di Mitoxantrone e risultati clinici. In: Giornale di Chirurgia. 1997 ; Vol. 18, No. 6-7. pp. 362-367.
@article{99c08eb71fac424889a7f312717ca7a9,
title = "Lipiodolizzazione associata o meno a Gelfoam in pazienti con tumore epatico primitivo. Livelli plasmatici di Mitoxantrone e risultati clinici.",
abstract = "Transcatheter chemoembolization with various drugs is employed for palliative treatment of hepatocellular carcinoma. Thirty-seven patients (33 with Child A or B cirrhosis) were treated with 14 mg/m2 of Mitoxantrone and up to 20 ml of Lipiodol, followed by Gelfoam embolization as indicated. Sixty-nine cycles were given, with mean (+/-SD) Lipiodol and emulsified Mitoxantrone doses of 11.3 +/- 3.8 ml and 11.8 +/- 5.2 mg, respectively. Thirteen, 16, and 8 patients received one, two, and three cycles, respectively, with time intervals of 123 +/- 60 days. Thirty patients had Gelfoam embolization at the first cycle, 9 at the second and 4 at the third. At the first cycle, 10 patients underwent serial measurements of serum Mitoxantrone up to two hours after a full dose of emulsified drug. Drug levels resulted much lower than those reported after plain arterial infusion, with AUC levels (+/-SE) of 5924 +/- 1015 and 4381 +/- 429 ng/ml x 120 min in 6 and 4 cases treated with and without Gelfoam, respectively. No treatment related deaths occurred. Complications were mild and transient, including nausea vomiting in most cases, fever > 38 degrees C 67{\%}, pain 74{\%}, ascites 8{\%} jaundice 3{\%}, bleeding 3{\%}, pancreatitis 3{\%}, myelosuppression 44{\%}, diarrhea 5{\%}. Treatment response rate was 49{\%} (including 16{\%} minor response) with 16{\%} early progressions. With a median follow-up of 12 months, the 12-month response duration and survival rates were 56{\%} and 79{\%} respectively. Transcatheter chemoembolization with Mitoxantrone deserves further evaluation in randomized studies.",
author = "D. Civalleri and M. Esposito and {De Caro}, G. and G. Borgonovo and {De Cian}, F. and G. Mondini and O. Vannozzi and Bocchio, {M. M.} and S. Carrabetta",
year = "1997",
month = "6",
language = "Italian",
volume = "18",
pages = "362--367",
journal = "Giornale di Chirurgia",
issn = "0391-9005",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "6-7",

}

TY - JOUR

T1 - Lipiodolizzazione associata o meno a Gelfoam in pazienti con tumore epatico primitivo. Livelli plasmatici di Mitoxantrone e risultati clinici.

AU - Civalleri, D.

AU - Esposito, M.

AU - De Caro, G.

AU - Borgonovo, G.

AU - De Cian, F.

AU - Mondini, G.

AU - Vannozzi, O.

AU - Bocchio, M. M.

AU - Carrabetta, S.

PY - 1997/6

Y1 - 1997/6

N2 - Transcatheter chemoembolization with various drugs is employed for palliative treatment of hepatocellular carcinoma. Thirty-seven patients (33 with Child A or B cirrhosis) were treated with 14 mg/m2 of Mitoxantrone and up to 20 ml of Lipiodol, followed by Gelfoam embolization as indicated. Sixty-nine cycles were given, with mean (+/-SD) Lipiodol and emulsified Mitoxantrone doses of 11.3 +/- 3.8 ml and 11.8 +/- 5.2 mg, respectively. Thirteen, 16, and 8 patients received one, two, and three cycles, respectively, with time intervals of 123 +/- 60 days. Thirty patients had Gelfoam embolization at the first cycle, 9 at the second and 4 at the third. At the first cycle, 10 patients underwent serial measurements of serum Mitoxantrone up to two hours after a full dose of emulsified drug. Drug levels resulted much lower than those reported after plain arterial infusion, with AUC levels (+/-SE) of 5924 +/- 1015 and 4381 +/- 429 ng/ml x 120 min in 6 and 4 cases treated with and without Gelfoam, respectively. No treatment related deaths occurred. Complications were mild and transient, including nausea vomiting in most cases, fever > 38 degrees C 67%, pain 74%, ascites 8% jaundice 3%, bleeding 3%, pancreatitis 3%, myelosuppression 44%, diarrhea 5%. Treatment response rate was 49% (including 16% minor response) with 16% early progressions. With a median follow-up of 12 months, the 12-month response duration and survival rates were 56% and 79% respectively. Transcatheter chemoembolization with Mitoxantrone deserves further evaluation in randomized studies.

AB - Transcatheter chemoembolization with various drugs is employed for palliative treatment of hepatocellular carcinoma. Thirty-seven patients (33 with Child A or B cirrhosis) were treated with 14 mg/m2 of Mitoxantrone and up to 20 ml of Lipiodol, followed by Gelfoam embolization as indicated. Sixty-nine cycles were given, with mean (+/-SD) Lipiodol and emulsified Mitoxantrone doses of 11.3 +/- 3.8 ml and 11.8 +/- 5.2 mg, respectively. Thirteen, 16, and 8 patients received one, two, and three cycles, respectively, with time intervals of 123 +/- 60 days. Thirty patients had Gelfoam embolization at the first cycle, 9 at the second and 4 at the third. At the first cycle, 10 patients underwent serial measurements of serum Mitoxantrone up to two hours after a full dose of emulsified drug. Drug levels resulted much lower than those reported after plain arterial infusion, with AUC levels (+/-SE) of 5924 +/- 1015 and 4381 +/- 429 ng/ml x 120 min in 6 and 4 cases treated with and without Gelfoam, respectively. No treatment related deaths occurred. Complications were mild and transient, including nausea vomiting in most cases, fever > 38 degrees C 67%, pain 74%, ascites 8% jaundice 3%, bleeding 3%, pancreatitis 3%, myelosuppression 44%, diarrhea 5%. Treatment response rate was 49% (including 16% minor response) with 16% early progressions. With a median follow-up of 12 months, the 12-month response duration and survival rates were 56% and 79% respectively. Transcatheter chemoembolization with Mitoxantrone deserves further evaluation in randomized studies.

UR - http://www.scopus.com/inward/record.url?scp=0031158408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031158408&partnerID=8YFLogxK

M3 - Articolo

C2 - 9296600

AN - SCOPUS:0031158408

VL - 18

SP - 362

EP - 367

JO - Giornale di Chirurgia

JF - Giornale di Chirurgia

SN - 0391-9005

IS - 6-7

ER -